Risks stratification and benefits of PCI
Percutaneous coronary intervention Microchapters
Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT
PCI in Specific Patients
PCI in Specific Lesion Types
Risks stratification and benefits of PCI On the Web
American Roentgen Ray Society Images of Risks stratification and benefits of PCI
Directions to Hospitals Treating Percutaneous coronary intervention
Risk calculators and risk factors for Risks stratification and benefits of PCI
Editor-In-Chief: C. Michael Gibson, M.S., M.D. ; Associate Editor(s)-in-Chief: Xin Yang, MA(Cantab), MB BChir, MRCP(Lond) Anahita Deylamsalehi, M.D.
There are several risk assessment scores which can help in determining a patient's risk for death, myocardial infarction and recurrent cardiac events.
Risks Stratification and Benefits of PCI
Risk Score Assessment
The TIMI Risk Score for STEMI
The TIMI Risk Score for UA/NSTEMI
The GRACE Risk Score
Risk Stratification Tools
Risk Stratification in the Patient with Stable Angina
Risk Stratification in the Patient with Unstable Angina or Non ST Elevation MI
Risk Stratification in the Patient with ST Elevation MI
Benefits of PCI vs Medical Therapy
In Patients With Stable Angina
In Patients With Unstable Angina or Non ST Elevation MI
In Patients With ST Elevation MI
Benefits of Rescue PCI
Studies demonstrated that rescue PCI after failed fibrinolytic therapy is related to a lower risk of cardiovascular events when compared to repeated fibrinolytic therapy or conservative managements.
- However, rates of complications such as stroke and bleeding were higher in the rescue PCI group.
- On the other hand, the fact that those studies have been done in the era of femoral artery access and limited antiplatelet and anticoagulant therapies may explain the higher rates of stroke and bleeding.
- Half-dose tenecteplase in patients older than 75 years old reduces the risk of stroke.
- Furthermore, radial artery access instead of femoral artery or avoiding routine use of glycoprotein IIb/IIIa inhibitors could be used to decrease the risk of bleeding.
- ↑ 1.0 1.1 Sutton AG, Campbell PG, Graham R, Price DJ, Gray JC, Grech ED; et al. (2004). "A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial". J Am Coll Cardiol. 44 (2): 287–96. doi:10.1016/j.jacc.2003.12.059. PMID 15261920.
- ↑ 2.0 2.1 Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JM, Krumholz HM, Phillips CO; et al. (2007). "Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials". J Am Coll Cardiol. 49 (4): 422–30. doi:10.1016/j.jacc.2006.09.033. PMID 17258087. Review in: ACP J Club. 2007 Jul-Aug;147(1):11
- ↑ Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A (2006). "Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy". J Am Coll Cardiol. 48 (7): 1326–35. doi:10.1016/j.jacc.2006.03.064. PMID 17010790.
- ↑ 4.0 4.1 Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM; et al. (2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006. PMID 34895950 Check
- ↑ Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y; et al. (2013). "Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction". N Engl J Med. 368 (15): 1379–87. doi:10.1056/NEJMoa1301092. PMID 23473396.
- ↑ Mason PJ, Shah B, Tamis-Holland JE, Bittl JA, Cohen MG, Safirstein J; et al. (2018). "An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association". Circ Cardiovasc Interv. 11 (9): e000035. doi:10.1161/HCV.0000000000000035. PMID 30354598.